Patents Assigned to The Washington University
  • Patent number: 12152280
    Abstract: The present invention provides methods for testing surgical fluid for biomarkers of disease, including cancer.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: November 26, 2024
    Assignees: DROPLET BIOSCIENCES, INC., The Washington University
    Inventors: Jose P. Zevallos, Aadel Chaudhuri, Stanley N. Lapidus
  • Patent number: 11920139
    Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: March 5, 2024
    Assignees: The Washington University, The Arizona Board of Regents for and on Behalf of Arizona State University
    Inventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
  • Publication number: 20220001189
    Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to he positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of tire one or more singularities delivered via the near-field configuration of the electrodes.
    Type: Application
    Filed: July 19, 2021
    Publication date: January 6, 2022
    Applicant: The Washington University
    Inventors: Igor R. EFIMOV, Wenwen LI, Ajit JANARDHAN
  • Patent number: 11180765
    Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: November 23, 2021
    Assignees: The Arizona Board of Regents for and on behalf of Arizona State University, The Washington University
    Inventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
  • Patent number: 11097120
    Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: August 24, 2021
    Assignee: The Washington University
    Inventors: Igor R. Efimov, Wenwen Li, Ajit Janardhan
  • Patent number: 11083905
    Abstract: Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: August 10, 2021
    Assignee: The Washington University
    Inventors: Igor R. Efimov, Wenwen Li, Ajit H. Janardhan
  • Patent number: 10774334
    Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: September 15, 2020
    Assignees: Arizona Broad of Regents on Behalf of Arizona State University, The Washington University
    Inventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
  • Patent number: 10549108
    Abstract: A method for extinguishing a cardiac arrhythmia utilizes destructive interference of the passing of the reentry wave tip of an anatomical reentry through a depolarized region created by a relatively low voltage electric field in such a way as to effectively unpin the anatomical reentry. Preferably, the relatively low voltage electric field is defined by at least one unpinning shock(s) that are lower than an expected lower limit of vulnerability as established, for example, by a defibrillation threshold test. By understanding the physics of the electric field distribution between cardiac cells, the method permits the delivery of an electric field sufficient to unpin the core of the anatomical reentry, whether the precise or estimated location of the reentry is known or unknown and without the risk of inducting ventricular fibrillation. A number of embodiments for performing the method are disclosed.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: February 4, 2020
    Assignee: The Washington University
    Inventors: Igor R. Efimov, Valentin Krinski, Vladmir P. Nikolski
  • Publication number: 20190366109
    Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.
    Type: Application
    Filed: August 6, 2019
    Publication date: December 5, 2019
    Applicant: The Washington University
    Inventors: Igor R. EFIMOV, Wenwen LI, Ajit JANARDHAN
  • Publication number: 20190358463
    Abstract: Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.
    Type: Application
    Filed: August 6, 2019
    Publication date: November 28, 2019
    Applicant: The Washington University
    Inventors: Igor R. Efimov, Wenwen Li, Ajit H. Janardhan
  • Patent number: 10441805
    Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: October 15, 2019
    Assignee: The Washington University
    Inventors: Igor R. Efimov, Wenwen Li, Ajit Janardhan
  • Patent number: 10413741
    Abstract: Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: September 17, 2019
    Assignee: The Washington University
    Inventors: Igor R. Efimov, Wenwen Li, Ajit H. Janardhan
  • Patent number: 9885051
    Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: February 6, 2018
    Assignees: The Arizona Board of Regents for and on Behalf of Arizona State University, The Washington University
    Inventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
  • Patent number: 9814895
    Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: November 14, 2017
    Assignee: The Washington University
    Inventors: Igor R. Efimov, Wenwen Li, Ajit Janardhan
  • Patent number: 9297015
    Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: March 29, 2016
    Assignees: Arizona Board of Regents for and on behalf of Arizona State University, The Washington University
    Inventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
  • Patent number: 9289620
    Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: March 22, 2016
    Assignee: The Washington University
    Inventors: Igor R. Efimov, Wenwen Li, Ajit Janardhan
  • Publication number: 20150045847
    Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.
    Type: Application
    Filed: April 21, 2014
    Publication date: February 12, 2015
    Applicant: The Washington University
    Inventors: Igor R. EFIMOV, Wenwen LI, Ajit JANARDHAN
  • Patent number: 8874208
    Abstract: Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: October 28, 2014
    Assignee: The Washington University
    Inventors: Igor R. Efimov, Wenwen Li, Ajit Janardhan
  • Publication number: 20140234841
    Abstract: In one aspect, the disclosure provides isolated nucleic acids, polypeptides, primers, and probes for the detection of mutations in a nucleic acid sequence for a DICER1 polypeptide.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicants: Children's Hospital and Clinics of Minnesota, The Washington University in St. Louis
    Inventors: Ashley D. Hill, Paul Goodfellow, John R. Priest, Yoav Messinger
  • Publication number: 20140221614
    Abstract: A mineralized collagen matrix with an intrafibrillar and/or extrafibrillar gradient of mineralization for insertion replacement is disclosed. The intrafibrillar mineralization of the collagen matrix is formed by the addition of fetuin to the simulated body fluid. The gradient of intrafibrillar mineralization may stiffen the collagen matrix and simulate a natural insertion for improved cell infiltration and regeneration.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 7, 2014
    Applicant: The Washington University
    Inventors: Lester Smith, Stavros Thomopoulos